Publicaciones en las que colabora con Fermín Sánchez-Guijo Martín (31)

2023

  1. Uncovering perturbations in human hematopoiesis associated with healthy aging and myeloid malignancies at single-cell resolution

    eLife, Vol. 12

2022

  1. The transcription factor DDIT3 is a potential driver of dyserythropoiesis in myelodysplastic syndromes

    Nature Communications, Vol. 13, Núm. 1

2014

  1. Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: Implications in myeloma progression and myeloma bone disease

    Oncotarget, Vol. 5, Núm. 18, pp. 8284-8305

2013

  1. Analysis of incidence, risk factors and clinical outcome of thromboembolic and bleeding events in 431 allogeneic hematopoietic stem cell transplantation recipients

    Haematologica, Vol. 98, Núm. 3, pp. 437-443

  2. Uptake and delivery of antigens by mesenchymal stromal cells

    Cytotherapy, Vol. 15, Núm. 6, pp. 673-678

2012

  1. Allogeneic mesenchymal stem cell therapy for refractory cytopenias after hematopoietic stem cell transplantation

    Transfusion, Vol. 52, Núm. 5, pp. 1086-1091

  2. Dasatinib as a bone-modifying agent: Anabolic and anti-resorptive effects

    PLoS ONE, Vol. 7, Núm. 4

  3. Optimisation of mesenchymal stromal cells karyotyping analysis: Implications for clinical use

    Transfusion Medicine, Vol. 22, Núm. 2, pp. 122-127

2011

  1. Effect of vitamin D treatment in chronic GVHD

    Bone Marrow Transplantation

2010

  1. Both CD133+ cells and monocytes provide significant improvement for hindlimb ischemia, although they do not transdifferentiate into endothelial cells

    Cell Transplantation, Vol. 19, Núm. 1, pp. 103-112

  2. Isolation and characterization of mesenchymal stromal cells from human degenerated nucleus pulposus: Comparison with bone marrow mesenchymal stromal cells from the same subjects

    Spine, Vol. 35, Núm. 26, pp. 2259-2265

  3. Liver function tests and absolute lymphocyte count at day +100 are predictive factors for extensive and severe chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplant

    American Journal of Hematology, Vol. 85, Núm. 4, pp. 290-293

2009

  1. Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q- syndrome

    Leukemia, Vol. 23, Núm. 4, pp. 664-672

  2. Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors

    Leukemia, Vol. 23, Núm. 8, pp. 1515-1527

  3. Oral Beclomethasone Dipropionate for the Treatment of Gastrointestinal Chronic Graft-versus-Host Disease

    Biology of Blood and Marrow Transplantation, Vol. 15, Núm. 10, pp. 1331-1336

  4. Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population

    Haematologica, Vol. 94, Núm. 7, pp. 975-983

2008

  1. Optimization of mesenchymal stem cell expansion procedures by cell separation and culture conditions modification

    Experimental Hematology, Vol. 36, Núm. 8, pp. 1014-1021

  2. Prognostic Factors of Chronic Graft-versus-Host Disease Following Allogeneic Peripheral Blood Stem Cell Transplantation: The National Institutes Health Scale Plus the Type of Onset Can Predict Survival Rates and the Duration of Immunosuppressive Therapy

    Biology of Blood and Marrow Transplantation, Vol. 14, Núm. 10, pp. 1163-1171

  3. The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes

    Haematologica, Vol. 93, Núm. 9, pp. 1301-1309

2007

  1. In leukapheresis products from non-Hodgkin's lymphoma patients, the immature hematopoietic progenitors show higher CD90 and CD34 antigenic expression

    Transfusion and Apheresis Science, Vol. 37, Núm. 2, pp. 145-156